Impact ledger
Amgen Inc. (AMGN)
30 events mapped to this ticker since 2026-06-12.
Event impact log
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-07-17 | Event | Increased competitive pressure in the nephrology and immunology space, potentially impacting future pipeline development or market share for existing/future drugs. | watch | 1-3m | 0.30 |
| 2026-07-17 | Event | Potential for increased R&D focus and competition in kidney disease treatments, influencing future pipeline decisions. | watch | 1-5y | 0.20 |
| 2026-07-15 | Event | Indirect competitive pressure in the broader oncology market, potentially influencing R&D strategies and market dynamics for targeted therapies. | watch | 1-3m | 0.15 |
| 2026-07-14 | Event | Broader sector sentiment and potential for future M&A activity in the autoimmune space. | watch | 3-12m | 0.20 |
| 2026-07-13 | Event | Increased competitive pressure in the broader pharmaceutical market, particularly for companies with pipeline assets in metabolic diseases or those reliant on older blockbuster drugs. | watch | 1-5y | 0.40 |
| 2026-07-11 | Event | Indirect competitive pressure and investor re-evaluation of obesity/diabetes pipeline assets. While not a direct competitor in the same class, the broader market sentiment around GLP-1s and NVO's challenges could prompt a closer look at other large biopharma companies with related R&D. | watch | 3-12m | 0.40 |
| 2026-07-08 | Event | Similar to Biogen, Amgen is a large biotech company that frequently uses M&A to bolster its pipeline and diversify. This deal could signal a more competitive M&A environment or influence Amgen's strategic considerations for future acquisitions, particularly in rare diseases. | watch | 3-12m | 0.40 |
| 2026-07-05 | Event | Increased competitive pressure in the immunology therapeutic area, potential for sector-wide valuation adjustments. | watch | 1-3m | 0.30 |
| 2026-07-05 | Event | Increased competition in the immunology/anti-inflammatory space, potentially impacting future market share or pricing power for existing products. | watch | 1-3m | 0.30 |
| 2026-06-30 | Event | Amgen, a large biotechnology company, could be a target for pharma giants or an active acquirer of smaller biotech firms to expand its pipeline and mitigate competitive pressures. | watch | 3-12m | 0.60 |
| 2026-06-30 | Event | Indirect competitive pressure in the broader dermatology/psoriasis market. | watch | 3-12m | 0.15 |
| 2026-06-30 | Event | Increased competition and potentially lower market share for Amjevita (Amgen's Humira biosimilar) if patient re-switching to branded Humira is significant, impacting sales forecasts. | Bearish | 1-3m | 0.50 |
| 2026-06-29 | Event | Indirect competitive landscape shift in the COPD market; potential for increased competition or strategic responses. | watch | 3-12m | 0.20 |
| 2026-06-29 | Event | Potential competitive landscape shift in therapeutic areas where Zymeworks/Theravance operate, or if Amgen has existing partnerships/investments with either company. | watch | 3-12m | 0.30 |
| 2026-06-26 | Event | As a major player in biologics, Amgen could face increased competitive intensity from J&J's strategic pivot and significant investment in this high-growth area, potentially impacting future pipeline development and market access. | watch | 1-3m | 0.40 |
| 2026-06-26 | Event | J&J's increased focus and investment in biologics could intensify competition in specific therapeutic areas, potentially impacting Amgen's market share or pricing power. | watch | 3-12m | 0.30 |
| 2026-06-23 | Event | Increased competitive pressure in the immunology market, particularly in eczema and asthma, where Amgen has existing or developing treatments. May prompt strategic re-evaluation or increased R&D spending. | watch | 1-3m | 0.30 |
| 2026-06-23 | Event | Increased competitive pressure in the immunology market due to AbbVie's strengthened pipeline; potential for other M&A targets to become more expensive. | watch | 1-3m | 0.30 |
| 2026-06-23 | Event | Increased competitive pressure in immunology market, potential for other M&A activity in the sector. | watch | 3-12m | 0.30 |
| 2026-06-23 | Event | Increased competitive pressure in the immunology market (eczema, asthma) from a strengthened AbbVie pipeline. Potential for increased R&D spending or M&A activity in response. | watch | 3-12m | 0.40 |
| 2026-06-23 | Event | Increased competition in the immunology market from a strengthened AbbVie, potentially impacting future market share or pricing power for immunology drugs. | watch | 3-12m | 0.30 |
| 2026-06-22 | Event | Indirect competitive pressure and potential shifts in R&D focus within the biopharmaceutical industry. Amgen has a diversified pipeline but less direct exposure to MDD. | watch | 3-12m | 0.10 |
| 2026-06-22 | Event | Increased competitive pressure in the immunology market, potentially impacting future market share or pricing power for existing and pipeline immunology assets. | watch | 1-3m | 0.30 |
| 2026-06-22 | Event | Increased competitive pressure in the immunology market, potential for other large pharma companies to seek similar acquisitions. | watch | 1-3m | 0.30 |
| 2026-06-17 | Event | Potential shift in competitive landscape for certain therapeutic areas or manufacturing capabilities. | watch | 1-5y | 0.10 |
| 2026-06-17 | Event | Amgen is developing an oral GLP-1 candidate (MariTide). The projected market growth and emphasis on oral formulations present a potential opportunity for Amgen to capture market share if their drug proves competitive. | watch | 3-12m | 0.50 |
| 2026-06-17 | Event | Potential for competitive pressure on existing and pipeline obesity/metabolic drugs if their GLP-1 candidate (MariTide) gains significant market traction, or conversely, if it underperforms against established leaders. Increased R&D spending to compete in the GLP-1 space. | watch | 1-5y | 0.60 |
| 2026-06-12 | Event | Potential future competition in the cardiovascular/lipid-lowering market, though current impact is indirect. | watch | 3-12m | 0.30 |
| 2026-06-12 | Event | Indirect competition. Amgen is developing its own obesity drug (MariTide). Strong performance by VKTX's VK2735 could intensify the competitive landscape, potentially influencing investor perception of other pipeline assets in the obesity space. | watch | 3-12m | 0.30 |
| 2026-06-12 | Event | Potential competitive pressure in the anemia treatment market, particularly if HUTCHMED's drug expands beyond China or targets similar patient populations. | watch | 1-5y | 0.30 |
This ledger is regenerated from Market Ontology's public event pipeline. For live alerts on new assumption changes for AMGN, start a trial or view the AMGN entity page.